Endocyte Inc. (Nasdaq: ECYT) entered an exclusive worldwide license for PSMA-617 and will begin Phase 3 development of Lu-PSMA-617 to treat prostate cancer. Shares of the biopharmaceutical surged $2.25 to close at $5.88.
Endocyte enters exclusive license
October 03, 2017 at 18:11 PM EDT
